Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
KIN's Cash to Debt is ranked higher than
74% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. KIN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KIN' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6682
N/A
No Debt
Interest Coverage No Debt
KIN's Interest Coverage is ranked higher than
64% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. KIN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KIN' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 22.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -32.24
KIN's ROE (%) is ranked higher than
51% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. KIN: -32.24 )
Ranked among companies with meaningful ROE (%) only.
KIN' s ROE (%) Range Over the Past 10 Years
Min: -33.44  Med: -30.94 Max: -13.32
Current: -32.24
-33.44
-13.32
ROA (%) -31.23
KIN's ROA (%) is ranked lower than
53% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. KIN: -31.23 )
Ranked among companies with meaningful ROA (%) only.
KIN' s ROA (%) Range Over the Past 10 Years
Min: -32.42  Med: -29.89 Max: -12.87
Current: -31.23
-32.42
-12.87
ROC (Joel Greenblatt) (%) -3065.19
KIN's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. KIN: -3065.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KIN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -70216.67  Med: -13415.27 Max: -3328.69
Current: -3065.19
-70216.67
-3328.69
» KIN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

KIN Guru Trades in Q2 2015

John Rogers 1,212,359 sh (+327.49%)
Jim Simons 177,855 sh (+55.06%)
Seth Klarman 3,013,848 sh (unchged)
» More
Q3 2015

KIN Guru Trades in Q3 2015

John Rogers 1,750,224 sh (+44.37%)
Seth Klarman 3,013,848 sh (unchged)
Jim Simons 119,810 sh (-32.64%)
» More
Q4 2015

KIN Guru Trades in Q4 2015

Chuck Royce 90,000 sh (New)
Jim Simons 265,902 sh (+121.94%)
John Rogers 2,498,179 sh (+42.73%)
Seth Klarman 3,013,848 sh (unchged)
» More
Q1 2016

KIN Guru Trades in Q1 2016

Chuck Royce 148,000 sh (+64.44%)
John Rogers 3,587,561 sh (+43.61%)
Seth Klarman 3,013,848 sh (unchged)
Jim Simons 217,900 sh (-18.05%)
» More
» Details

Insider Trades

Latest Guru Trades with KIN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:CWBR, NAS:INFI, OTCPK:INNMF, OTCPK:AMEUF, NAS:ONS, NAS:REPH, NAS:ZFGN, NAS:CERU, NAS:CAPR, NAS:OHRP, AMEX:NAVB, NAS:DMPI, NAS:TENX, NAS:QLTI, NAS:AKAO, NAS:GALE, OTCPK:HSDT, NAS:ABEO, NAS:NVLS, NAS:GTXI » details
Traded in other countries:17K.Germany,
Kindred Biosciences Inc is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. The Company's product candidates are SentiKind, KIND-010 and KIND-012.

Top Ranked Articles about Kindred Biosciences Inc

John Rogers Invests in Bristow Group, Kindred Biosciences Guru boosts Bristow stake by 24%
John Rogers (Trades, Portfolio), founder of Ariel Investment LLC, added to two stakes in his portfolio – Bristow Group Inc. (NYSE:BRS) and Kindred Biosciences Inc. (NASDAQ:KIN) – on March 31. Read more...
Guru John Rogers Raises Stake in Helping Animals Rogers ups stake in Kindred Biosciences by 45%
Guru John Rogers (Trades, Portfolio) is the founder of Ariel Investments, which is located in Chicago. It specializes in small and mid-cap stocks based in the U.S. Read more...

Ratios

vs
industry
vs
history
P/B 1.11
KIN's P/B is ranked higher than
89% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. KIN: 1.11 )
Ranked among companies with meaningful P/B only.
KIN' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 5.6
Current: 1.11
0
5.6
EV-to-EBIT -0.33
KIN's EV-to-EBIT is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. KIN: -0.33 )
Ranked among companies with meaningful EV-to-EBIT only.
KIN' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.5  Med: 0.00 Max: 5.83
Current: -0.33
-0.5
5.83
EV-to-EBITDA -0.34
KIN's EV-to-EBITDA is ranked lower than
99.99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. KIN: -0.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
KIN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.52  Med: 0.00 Max: 5.83
Current: -0.34
-0.52
5.83
Current Ratio 36.64
KIN's Current Ratio is ranked higher than
97% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. KIN: 36.64 )
Ranked among companies with meaningful Current Ratio only.
KIN' s Current Ratio Range Over the Past 10 Years
Min: 10.63  Med: 30.74 Max: 45.03
Current: 36.64
10.63
45.03
Quick Ratio 36.64
KIN's Quick Ratio is ranked higher than
97% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. KIN: 36.64 )
Ranked among companies with meaningful Quick Ratio only.
KIN' s Quick Ratio Range Over the Past 10 Years
Min: 10.63  Med: 30.74 Max: 45.03
Current: 36.64
10.63
45.03

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.17
KIN's Price/Net Cash is ranked higher than
94% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. KIN: 1.17 )
Ranked among companies with meaningful Price/Net Cash only.
KIN' s Price/Net Cash Range Over the Past 10 Years
Min: 0.97  Med: 1.54 Max: 5.19
Current: 1.17
0.97
5.19
Price/Net Current Asset Value 1.15
KIN's Price/Net Current Asset Value is ranked higher than
93% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. KIN: 1.15 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KIN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.96  Med: 1.53 Max: 5.15
Current: 1.15
0.96
5.15
Price/Tangible Book 1.09
KIN's Price/Tangible Book is ranked higher than
92% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. KIN: 1.09 )
Ranked among companies with meaningful Price/Tangible Book only.
KIN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.88  Med: 1.53 Max: 5.14
Current: 1.09
0.88
5.14
Earnings Yield (Greenblatt) (%) -292.25
KIN's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. KIN: -292.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KIN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -65947.24  Med: 0.00 Max: 10993.22
Current: -292.25
-65947.24
10993.22

More Statistics

EPS (TTM) $ -1.34
Short Percentage of Float0.89%
52-Week Range $2.90 - 6.38
Shares Outstanding (Mil)19.84

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 1 9 56
EPS ($) -1.80 -1.60 -0.75
EPS w/o NRI ($) -1.80 -1.60 -0.75
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for KIN

Headlines

Articles On GuruFocus.com
John Rogers Invests in Bristow Group, Kindred Biosciences Apr 08 2016 
Guru John Rogers Raises Stake in Helping Animals Dec 16 2015 
Seth Klarman Nearly Doubles Stake in Atara Biotherapeutics Apr 15 2015 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 

More From Other Websites
Kinepolis Group NV :KIN-BE: Earnings Analysis: 2015 By the Numbers : July 25, 2016 Jul 25 2016
Kindred Biosciences Announces Initiation of Pilot Field Study of Atopic Dermatitis and Other Updates Jun 14 2016
Kindred Biosciences, Inc. :KIN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 Jun 10 2016
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 27 2016
Kindred Biosciences Announces HITS Sponsorship May 25 2016
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Other Events May 16 2016
Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-010 for the Management of... May 16 2016
KINDRED BIOSCIENCES, INC. Financials May 14 2016
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 05 2016
Kindred Bio reports 1Q loss May 05 2016
Kindred Bio reports 1Q loss May 05 2016
Kindred Biosciences Announces First Quarter 2016 Financial Results May 05 2016
Q1 2016 Kindred Biosciences Inc Earnings Release - After Market Close May 05 2016
Kindred Biosciences Submits KIND-010 New Animal Drug Application Technical Section for Chemistry,... May 04 2016
Kindred Biosciences to Announce First Quarter 2016 Financial Results Apr 25 2016
Two Little Gems Are Hidden Amid Small-Caps Apr 21 2016
Kindred Biosciences Elects Herbert D. Montgomery to Join Its Board of Directors Apr 15 2016
Kindred Biosciences, Inc. (KIN): Hedge Funds and Value Investors Are Crazy About It Apr 08 2016
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers Apr 05 2016
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix Apr 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)